Received by email:

File: CURE - News Release Warrants CCI May 2018.doc

News Release
May 31, 2018
FOR IMMEDIATE RELEASE  

BioCure Technology Inc. announces issuance of warrants 
Vancouver, British Columbia - BioCure Technology Inc. (CSE: CURE) ("BioCure" or the "Company") has issued an aggregate
---> of 1.89 million share purchase warrants with an exercise price of $0.63 per share. The warrants are issuable pursuant
---> to a services agreement dated March 22, 2017, as amended and originally entered into by the company's wholly owned su
--->bsidiary, Biocurepharm Corp., with Columbia Capital Inc. Pursuant to the agreement, CCI was, among other things, entit
--->led to a success fee in relation to the completion of the company's acquisition of BP Korea, of warrants to acquire up
---> to 5 per cent of the outstanding shares of BP Korea. BP Korea and CCI previously agreed that this fee would be settle
--->d through the issuance of warrants to acquire 3.79 million common shares of the company at an exercise price and for a
---> term to be determined, which warrants would be issued within six months of the completion of the transaction. 
About Biocure Technology Inc. 
Biocure is a South Korean-based biopharmaceutical company specializing in the development and potential commercializat
--->ion of biosimilar pharmaceutical products. Biocure is in the process of preclinical trials of five major biosimilar pr
--->oducts in South Korea, including interferon beta 1b, PEG-filgrastim and ranibizumab, as well as CAR-T-cell therapy. Bi
--->ocure is also developing a foot and mouth disease vaccine, a hair growth production product, and a breast cancer detec
--->tion kit. 

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ "Sang Mok Lee"
      CEO and Director
For further information, please contact: 
Biocure Technology Inc. Telephone: 604-609-7149
Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" w
--->ithin the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limit
--->ed to, statements or information concerning the Company's proposed activities under the Agreement and the expectations
---> of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's curren
--->t assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown ri
--->sks and uncertainties and other factors which may cause actual results, performance or events to be materially differe
--->nt from those expressed or implied by such forward looking statements. Except as required pursuant to applicable secur
--->ities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the 
--->date hereof. More detailed information about potential factors that could affect financial results is included in the 
--->documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are caut
--->ioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") 
--->nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of 
--->this release.